2017 Will Be A Critical Year For Keytruda And Merck |
| May 06, 2017 | May 2017 Bond Updates |
|
Merck recently reported its Q1 2017 earnings, and while the results beat consensus estimates, the company’s stock didn’t move much because of concerns around Keytruda’s future growth. |
| View more at: http://www.forbes.com/sites/greatspeculations/2017/05/05/2017-will-be-a-critical-year-for-keytruda-and-merck/ |
| Related News |
|